Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Some iron-overloaded patients have problems being treated with iron chelators. We therefore retrospectively studied 7 iron-overloaded thalassemic patients. Within the same week, patients received 20 to 30 mg/kg/d of oral deferasirox for 4 consecutive days, then a subcutaneous infusion of 20 to 40 mg/kg/d of desferrioxamine for 8 to 12 hours on the next 3 consecutive days. The median treatment duration was 25 months (range, 8 to 32). All of the patients showed a decrease in serum ferritin without any side effects. The protocol, combining deferasirox and desferrioxamine in sequence, was effective and safe: more cases should be studied.
Jetsrisuparb
Arunee
A
Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. arujet@kku.ac.th
Komvilaisak
Patcharee
P
Wiangnon
Surapon
S
Jetsrisuparb
Charoon
C
D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000627:therapeutic use*; D002648:Child; D000077588:Deferasirox; D003676:Deferoxamine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy*; D008297:Male; D012189:Retrospective Studies; D017262:Siderophores / Q000627:therapeutic use*; D015996:Survival Rate; D013789:Thalassemia / Q000188:drug therapy*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D055815:Young Adult
D001565:Benzoates; D007502:Iron Chelating Agents; D017262:Siderophores; D014230:Triazoles; D005293:Ferritins; D003676:Deferoxamine; D000077588:Deferasirox